Clinical trials: Skin Diseases, Papulosquamous
Arthritis, Arthritis, Juvenile Idiopathic
Pain in Inflammatory Joint Diseases
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus…
- Conditions
- Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid, Arthritis, Reactive
- Trial name
- Nor-Pain (NCT06718569)
- Testing
- Biological or targeted synthetic DMARD
- Where
- Norway
- Volunteers
- 350 people
- Sponsor
- Diakonhjemmet Hospital
Psoriatic Arthritis
Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA
Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear.
- Trial name
- MUST (NCT03148860)
- Testing
- Methotrexate, Ustekinumab
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Dr. Frank Behrens
Psoriasis
Trial of HSK44459 Cream for the Management Plaque Psoriasis
Phase I Study Objectives: Primary: Assess the safety and tolerability of HSK44459 cream in 10 healthy adult participants and 10 patients with plaque psoriasis.
- Trial name
- NCT07623486
- Testing
- HSK44459 Cream, Vehicle
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Psoriatic Arthritis
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study
Objectives: To identify a candidate set of biomarkers specific to AxPsA. Overview: Clinical and imaging characterization of PsA patients will be combined with extensive molecular assessment of both liquid and tissue compartments…
- Trial name
- MONOLITH (NCT05925842)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lichen Planus
Mucosal and Nasal Involvement and Their Correlation With Smell and Taste Functions in Lichen Planus Patients
This study investigates smell and taste function in patients diagnosed with lichen planus, a chronic inflammatory condition affecting the skin and mucous membranes.
- Trial name
- LP-NOSE (NCT07570706)
- Testing
- Grup 1 - Lichen Planus Patients Intervention Name: Taste and Smell Testing, Oral and Nasal Examination, Nasal Endoscopy Intervention Description: Participants undergo taste and smell testing to assess
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Psoriasis
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who…
- Trial name
- NCT00109252
- Testing
- Raptiva (efalizumab)
- Sponsor
- Genentech, Inc.
Lichen Planus
Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus
This study is designed to demonstrate to efficacy and safety of Apremilast 20mg oral administration twice daily over 12 weeks in subjects with moderate to severe lichen planus.
- Trial name
- NCT01041625
- Testing
- Apremilast (CC-10004)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Virginia Clinical Research, Inc.
Moderate to Severe Plaque Psoriasis
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to develop a database containing patient-reported information that may be used to understand and to increase awareness of the impact that moderate-to-severe plaque psoriasis can have on both daily life…
- Trial name
- NCT01555606
- Testing
- No intervention
- Where
- 9 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Biotech, Inc.
Psoriasis
CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.
Psoriasis is an immuno-mediated skin disorder, which affects about 2-3% of the population worldwide. For moderate-severe forms of psoriasis systemic immunosuppression is the treatment of choice.
- Trial name
- NCT00295425
- Testing
- Cyclosporine A versus mycophenolate mofetil for psoriasis
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Muenster
Plaque Psoriasis, Psoriasis
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
- Conditions
- Plaque Psoriasis, Psoriasis, Skin Diseases
- Trial name
- IMPACT-PS (NCT03832738)
- Testing
- JTE-451 Tablets
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Moderate to Severe Chronic Plaque-type Psoriasis
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03504852
- Testing
- secukinumab 150 mg
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 331 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
This is a multicenter, prospective, non-interventional, observational single arm study. 100 patients will be recruited in the Netherlands over a one year period.
- Trial name
- REWARD (NCT02875184)
- Where
- 21 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Amgen
Psoriasis
Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)
Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.
- Trial name
- NCT00725452
- Testing
- Infliximab
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis, Atherosclerosis
PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with an increased risk of myocardial infarction (MI). Using coronary computer tomography angiogram (CCTA), it is found that a significantly higher prevalence…
- Trial name
- NCT04176978
- Testing
- Rosuvastatin, Treat-to-target strategy
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
Rheumatoid Arthritis, Arthritis, Psoriatic
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.The objective of this study is to…
- Conditions
- Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis
- Trial name
- NCT01081717
- Testing
- systemic non-biological treatments, anti-TNF biologics, golimumab
- Volunteers
- 1,064 people
- Sponsor
- Janssen Biotech, Inc.
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites.
- Trial name
- NCT06666114
- Where
- Brazil
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Inflammation
Regulation of Inflammatory Genes in Psoriasis
Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of…
- Trial name
- NCT03125655
- Testing
- Inflammatory markers
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Psoriasis, Alopecia Areata
Improving Disease Severity
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions.
- Conditions
- Psoriasis, Alopecia Areata, Polymorphous Light Eruption
- Trial name
- NCT05391178
- Testing
- Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
- Trial name
- UNCOVER-1 (NCT01474512)
- Testing
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,296 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.